Nivolumab significantly improved overall survival (OS) vs investigator's choice (IC) of chemotherapy at the primary analysis of randomized, open-label, phase 3 CheckMate 141 in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). Here, we report that OS benefit with nivolumab was maintained at a minimum follow-up of 11.4 months. Further, OS benefit with nivolumab vs IC was also noted among patients who received first-line treatment for R/M SCCHN after progressing on platinum therapy for locally advanced disease in the adjuvant or primary (i.e., with radiation) setting.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221824PMC
http://dx.doi.org/10.1634/theoncologist.2017-0674DOI Listing

Publication Analysis

Top Keywords

checkmate 141
8
head neck
8
benefit nivolumab
8
141 1-year
4
1-year update
4
update subgroup
4
subgroup analysis
4
nivolumab
4
analysis nivolumab
4
nivolumab first-line
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!